Triple combination formula
ApprovedSmall molecule
Triple combination formula is one of 32 small molecule programs targeting Glaucoma. It is currently in Approved.
1
Indications
2
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
182 competitors in Glaucoma
#DrugCompanyPhaseTrials
1Lucentis
RochePhase 3
Namenda
AbbViePhase 3
Eylea
RegeneronPhase 3
Avastin
BBio-Thera Solutions
Phase 3
Viagra
VViatris Specialty LLC
Phase 3
Tocopherol
MM.D. Anderson Cancer Center
Phase 3
Triple combination formula
ZZagazig University
Approved
LUMIGAN
AbbViePhase 3
TFC-003
KKukje Pharma
Phase 3
T2345
LLaboratoires Thea
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Triple combination formula. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- ZZagazig University